Pacira BioSciences Dividends and Buybacks
Dividend criteria checks 0/6
Pacira BioSciences does not have a record of paying a dividend.
Key information
n/a
Dividend yield
2.1%
Buyback Yield
| Total Shareholder Yield | 2.1% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Pacira BioSciences: Back On An Uptrend After Positive Developments
Mar 14Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet
Jan 30
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 03Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Nov 25Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 06Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Jul 23These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely
Jun 07Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 05We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price
Jul 07Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28Assessing Pacira BioSciences' Growth Prospects
Oct 20Pacira BioSciences guides Q3 revenue below consensus
Oct 13Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if PCRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PCRX's dividend payments have been increasing.
Dividend Yield vs Market
| Pacira BioSciences Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PCRX) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (PCRX) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate PCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate PCRX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PCRX has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 22:38 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pacira BioSciences, Inc. is covered by 34 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |